Table 1.
Clinical and molecular characteristics of the evaluable patients in the Nivolumab Cohort and in the Chemotherapy Cohort. The Chemotherapy Cohort included only chemotherapy-naïve patients affected by non-squamous NSCLC with ECOG PS = 0–1.
| Clinical Characteristics | Nivolumab Cohort | Chemotherapy Cohort |
|---|---|---|
| n (%) | n (%) | |
| Patients | 46 | 27 |
| Gender | ||
| Male | 34 (73.9) | 20 (74.1) |
| Female | 12 (26.1) | 7 (25.9) |
| Age (year) | ||
| Range | 44–82 | 46–81 |
| Median | 70 | 69 |
| Smoking habit | ||
| Current | 13 (28.3) | 12 (44.4) 1 |
| Former | 24 (52.2) | 12 (44.4) 1 |
| Never | 9 (19.5) | 3 (11.1) 1 |
| Histology | ||
| Non-squamous | 35 (76.1) | 27 (100.0) |
| Squamous | 11 (23.9) | 0 (0.0) |
| Stage | ||
| IIIB | 2 (4.4) | 0 (0.0) |
| IV | 44 (95.6) | 27 (100.0) |
| ECOG PS | ||
| 0 | 17 (37.0) | 6 (22.2) |
| 1 | 26 (56.5) | 21 (77.8) |
| 2 | 3 (6.5) | 0 (0.0) |
| Previous lines of treatment | ||
| Range | 1–6 | - |
| Median | 2 | - |
| EGFR mutation | ||
| Yes | 3 (8.6) 2,4 | 1 (3.7) 3 |
| No | 32 (91.4) 4 | 26 (96.3) |
| ALK rearrangement | ||
| Yes | 0 (0.0) 4 | 0 (0.0) |
| No | 35 (100.0) 4 | 27 (100.0) |
1 Total = 99.9% due to approximation. 2 Two patients in the Nivolumab Cohort had exon 19 deletion, whereas one patient had exon 19 deletion in association with exon 20 insertion. 3 One patient in the Chemotherapy Cohort had exon 21 mutation, which was identified after first-line treatment. 4 Molecular screening for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements in the Nivolumab Cohort was performed in non-squamous NSCLC only (35/46).